Article
Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer.
BMJ open respiratory research - 1 Jun 2023
Batra Ullas, Biswas Bivas, Prabhash Kumar, Krishna M Vamshi
Abstract excerpt
The most common oncogenic driver in non-small-cell lung cancer (NSCLC) is the epidermal growth factor receptor (EGFR) gene mutations that occur more frequently among Asians (30%-50%) as opposed to Caucasians (10%-15%). Lung cancer is one of the most prevalent cancers in India, with a reported adenocarcinoma positivity ranging between 26.1% and 86.9% in NSCLC patients. The prevalence of EGFR mutations in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.